Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Chronic inflammatory demyelinating polyneuropathy (CIDP), also called chronic relapsing polyneuropathy, is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. Symptoms include initial limb weakness, both proximal and distal, orthostatic dizziness, tingling, and numbness of hands and feet.
The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drugs in Development market research report provides an overview of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and features dormant and discontinued projects.
CIDP Pipeline Drugs Market Targets
The targets of the CIDP pipeline drugs market are IgG Receptor FcRn Large Subunit p51, Cells Expressing B Lymphocyte Antigen CD20, Complement C1s Subcomponent, Envelope Protein, and T Cell Surface Glycoprotein CD4.
CIDP pipeline drugs market, by targets
For more target insights, download a free report sample
Mechanisms of Action of CIDP Pipeline Drugs Market
The mechanisms of action of the CIDP pipeline drugs market are IgG Receptor FcRn Large Subunit p51 Antagonist, Complement C1s Subcomponent Inhibitor, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, and T Cell Surface Glycoprotein CD4 Inhibitor.
CIDP pipeline drugs market, by mechanisms of action
For more mechanisms of action insights, download a free report sample
Routes of Administration in CIDP Pipeline Drugs Market
The routes of administration in the CIDP pipeline drugs market are intravenous, subcutaneous, and parenteral.
CIDP pipeline drugs market, by routes of administration
For more routes of administration insights, download a free report sample
Molecule Types in CIDP Pipeline Drugs Market
The molecule types in the CIDP pipeline drugs market are monoclonal antibody, antibody, cell therapy, fusion protein, recombinant enzyme, and synthetic peptide.
CIDP pipeline drugs market, by molecule types
For more molecule type insights, download a free report sample
Key CIDP Pipeline Drugs Market Companies
Some of the key companies in the CIDP pipeline drugs market are Argenx SE, Octapharma AG, Takeda Pharmaceutical Co Ltd, Biogen Inc, Cellenkos Inc, GeNeuro SA, HanAll Biopharma Co Ltd, Immupharma Plc, Johnson & Johnson, and Pfizer Inc.
CIDP pipeline drugs market, by key companies
To know more about key companies, download a free report sample
Market report overview
Targets | IgG Receptor FcRn Large Subunit p51, Cells Expressing B Lymphocyte Antigen CD20, Complement C1s Subcomponent, Envelope Protein, and T Cell Surface Glycoprotein CD4 |
Mechanisms of Action | IgG Receptor FcRn Large Subunit p51 Antagonist, Complement C1s Subcomponent Inhibitor, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, and T Cell Surface Glycoprotein CD4 Inhibitor |
Routes of Administration | Intravenous, Subcutaneous, and Parenteral |
Molecule Types | Monoclonal Antibody, Antibody, Cell Therapy, Fusion Protein, Recombinant Enzyme, and Synthetic Peptide |
Key Companies | Argenx SE, Octapharma AG, Takeda Pharmaceutical Co Ltd, Biogen Inc, Cellenkos Inc, GeNeuro SA, HanAll Biopharma Co Ltd, Immupharma Plc, Johnson & Johnson, and Pfizer Inc |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System).
- Reviews of pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Reviews of key companies involved in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) therapeutics and enlists all their major and minor projects.
- Evaluation of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) targeted therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news and deals related to pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Biogen Inc
Cellenkos Inc
GeNeuro SA
HanAll Biopharma Co Ltd
Immupharma Plc
Johnson & Johnson
Octapharma AG
Pfizer Inc
Sanofi
Takeda Pharmaceutical Co Ltd
UCB SA
Table of Contents
Table
Figures
Frequently asked questions
-
What are the targets of the CIDP pipeline drugs market?
The targets of the CIDP pipeline drugs market are IgG Receptor FcRn Large Subunit p51, Cells Expressing B Lymphocyte Antigen CD20, Complement C1s Subcomponent, Envelope Protein, and T Cell Surface Glycoprotein CD4.
-
What are the mechanisms of action of the CIDP pipeline drugs market?
The mechanisms of action of the CIDP pipeline drugs market are IgG Receptor FcRn Large Subunit p51 Antagonist, Complement C1s Subcomponent Inhibitor, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, and T Cell Surface Glycoprotein CD4 Inhibitor.
-
What are the routes of administration in the CIDP pipeline drugs market?
The routes of administration in the CIDP pipeline drugs market are intravenous, subcutaneous, and parenteral.
-
What are the molecule types in the CIDP pipeline drugs market?
The molecule types in the CIDP pipeline drugs market are monoclonal antibody, antibody, cell therapy, fusion protein, recombinant enzyme, and synthetic peptide.
-
Which are the key companies in the CIDP pipeline drugs market?
Some of the key companies in the CIDP pipeline drugs market are Argenx SE, Octapharma AG, Takeda Pharmaceutical Co Ltd, Biogen Inc, Cellenkos Inc, GeNeuro SA, HanAll Biopharma Co Ltd, Immupharma Plc, Johnson & Johnson, and Pfizer Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.